STOCK TITAN

Crinetics Pharmaceuticals, Inc. - CRNX STOCK NEWS

Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Founded with a mission to create impactful treatments, Crinetics focuses on advancing its innovative pipeline of orally delivered small molecule drugs.

The company's leading product candidate, paltusotine, is an investigational somatostatin receptor type 2 (SST2) agonist, currently in Phase 3 development for acromegaly and Phase 2 for carcinoid syndrome associated with neuroendocrine tumors. Paltusotine promises a convenient, once-daily oral treatment alternative to monthly injections, simplifying patient care and improving quality of life.

Moreover, Crinetics is advancing CRN04894 (atumelnant), a first-in-class oral ACTH antagonist in Phase 2 trials for congenital adrenal hyperplasia and ACTH-dependent Cushing's disease. This promising candidate aims to address significant unmet needs in these patient populations by reducing disease drivers and normalizing hormone levels.

Crinetics' in-house drug discovery efforts have resulted in several ongoing programs targeting conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity. The company's robust pipeline highlights its commitment to developing transformative therapies for patients with rare endocrine disorders.

Recent achievements include a successful private placement of $350 million, strengthening their financial position to support ongoing research and development. The company also reported positive topline results from its Phase 2 study of paltusotine for carcinoid syndrome, as well as from its Phase 3 PATHFNDR-2 study for acromegaly, reinforcing the potential of paltusotine in providing both symptom and biochemical control.

With strategic partnerships, including collaborations with top institutional investors and the National Institutes of Health, Crinetics is well-positioned for future growth. The company remains committed to bringing innovative treatments to market and improving the lives of patients worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags
none
-
Rhea-AI Summary
Crinetics Pharmaceuticals reports financial results for Q1 2023 and provides updates on its clinical programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
-
Rhea-AI Summary

On April 10, 2023, Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the grant of non-qualified stock options to 15 new non-executive employees, totaling 311,700 shares under the 2021 Employment Inducement Incentive Award Plan. These options, aimed at attracting new talent, have an exercise price of $16.02 per share, equivalent to the closing stock price on the grant date. The options will vest over four years, incentivizing continued employment. Crinetics focuses on developing innovative therapeutics for rare endocrine diseases and related tumors, with ongoing clinical trials for its drug candidates, including Paltusotine for acromegaly. The company aims to address significant unmet medical needs in this niche area.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on March 10, 2023, that its Board of Directors granted stock options to purchase 250,300 shares of common stock to eight new non-executive employees. These options were awarded under the 2021 Employment Inducement Incentive Award Plan, aimed at attracting new talent in line with Nasdaq regulations. The exercise price is set at $17.28 per share, matching the closing stock price on the grant date. The options will vest over four years, with the first 25% vesting after one year and the remainder monthly thereafter, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
none
-
Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the completion of enrollment for the Phase 3 PATHFNDR-1 study of paltusotine in acromegaly, with topline data expected in Q3 2023. The ongoing PATHFNDR-2 study's topline data is now anticipated in Q1 2024. A New Drug Application (NDA) submission for paltusotine is projected for 2024, pending successful outcomes from PATHFNDR studies. In 2022, the company reported a net loss of $163.9 million on revenues of $4.7 million. Despite increased R&D expenses totaling $130.2 million, Crinetics maintains a cash reserve of $334.4 million, projected to sustain operations into 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Radionetics Oncology has appointed Istvan Molnar, M.D. as the new Chief Medical Officer, bringing 15 years of oncology clinical development experience. This strategic hire is critical as the company plans to file three Investigational New Drug (IND) applications in 2023 and 2024, focusing on radiopharmaceuticals aimed at redefining cancer treatment standards. Dr. Molnar has a strong background in regulatory submissions and has successfully led late-stage oncology projects. The growing radiopharmaceutical market is projected to reach $12.6 billion by 2027, emphasizing the potential for Radionetics' innovative therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
management
Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on February 10, 2023, that its Board of Directors granted non-qualified stock options for an aggregate of 90,000 shares to six new non-executive employees. This issuance is part of the 2021 Employment Inducement Incentive Award Plan, designed to attract non-previously employed individuals to the company. The options have an exercise price of $19.60, equal to the closing stock price on the grant date, and will vest over four years. This initiative is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to bolster talent acquisition in the clinical stage pharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
none
-
Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. Eastern Time. This virtual event, occurring from February 14-16, 2023, will showcase the company's progress in developing therapeutics for rare endocrine diseases and related tumors. Notably, Crinetics is advancing Paltusotine, an investigational SST2 agonist, through Phase 3 trials for acromegaly and Phase 2 for carcinoid syndrome. The live broadcast and archived version will be available on the Events & Presentations page of Crinetics’ website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
conferences
-
Rhea-AI Summary

Crinetics Pharmaceuticals (CRNX) is advancing its clinical trials with key milestones expected in 2023. The Phase 3 PATHFNDR trials of paltusotine for acromegaly are on track for topline data readouts in 2H 2023, with plans to submit data for regulatory approval if successful. Additionally, a Phase 2 trial of paltusotine in carcinoid syndrome is anticipated to deliver topline data in 2H 2023. The company plans to initiate trials for CRN04894 targeting ACTH-dependent Cushing’s syndrome and congenital adrenal hyperplasia in Q1 2023, as part of its strategy to build a comprehensive endocrine-focused pipeline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
conferences
Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the granting of non-qualified stock options to twelve new non-executive employees on December 10, 2022. Under the 2021 Employment Inducement Incentive Award Plan, a total of 356,300 shares were awarded with an exercise price of $16.26, reflecting the fair market value at the time of the grant. These options will vest over four years, encouraging employee retention. This move aligns with Nasdaq Listing Rule 5635(c)(4), which allows for equity awards to induce employment for new hires.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none

FAQ

What is the current stock price of Crinetics Pharmaceuticals (CRNX)?

The current stock price of Crinetics Pharmaceuticals (CRNX) is $53.6 as of December 20, 2024.

What is the market cap of Crinetics Pharmaceuticals (CRNX)?

The market cap of Crinetics Pharmaceuticals (CRNX) is approximately 4.9B.

What does Crinetics Pharmaceuticals do?

Crinetics Pharmaceuticals specializes in the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

What are Crinetics' main product candidates?

Crinetics' main product candidates are paltusotine, in development for acromegaly and carcinoid syndrome, and CRN04894 (atumelnant), in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's disease.

What is paltusotine?

Paltusotine is an investigational, oral somatostatin receptor type 2 (SST2) agonist aimed at treating acromegaly and carcinoid syndrome.

What is CRN04894 (atumelnant)?

CRN04894, also known as atumelnant, is an investigational, first-in-class, oral ACTH antagonist in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's disease.

What recent achievements has Crinetics announced?

Crinetics recently secured $350 million through a private placement and reported positive topline results from its Phase 2 carcinoid syndrome study and Phase 3 PATHFNDR-2 study for acromegaly.

Who are some of Crinetics' key partners?

Crinetics collaborates with top institutional investors, such as Adage Capital Partners and Janus Henderson Investors, and has ongoing studies with the National Institutes of Health.

How does Crinetics aim to improve patient care?

Crinetics aims to improve patient care by developing orally delivered small molecule drugs that offer convenient alternatives to current treatments, potentially improving quality of life for patients with rare endocrine diseases.

What are some conditions Crinetics is targeting with its discovery programs?

Crinetics targets conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes, and obesity through its discovery programs.

How is Crinetics funded for its research and development?

Crinetics is funded through private placements and strategic partnerships with institutional investors, enabling continued research and development of its clinical-stage product candidates.

What is Crinetics' strategy for future growth?

Crinetics' strategy for future growth includes advancing its pipeline of novel therapeutics, collaborating with key partners, and bringing innovative treatments to market to address significant unmet needs in endocrine diseases.

Crinetics Pharmaceuticals, Inc.

Nasdaq:CRNX

CRNX Rankings

CRNX Stock Data

4.89B
89.30M
1.8%
94.7%
7.01%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO